Amgen has told a United States federal judge that it wouldn’t be “appropriate” to force it to hand over confidential correspondence, along with its advocacy to the Federal Trade Commission over a merger investigation, to plaintiff Regeneron Pharmaceuticals as part of a separate antitrust lawsuit.“We should be protective of
* = Required Field
*Areas of Interest
MLex content is primarily organized into seven Areas of Interest that cover the main elements of regulatory risk. Please indicate which ones you would like to be included in your Daily Wrap-up alert
MLex Limited and our LexisNexis Legal & Professional group of companies will use your personal information to administer your account and/or provide the products and services that you have requested from us. We may also contact you in your professional capacity with information about our other products, services and events that we believe may be of interest. You can manage your communication preferences via our Preference Center . You can learn more about how we handle your personal data and your rights by reviewing our Privacy Policy .
Khushita covers US antitrust enforcement and litigation for MLex. A former Brussels hand, she wrote about about antitrust & mergers for the Policy and Regulatory Report (PaRR), she has covered the EU's actions against Google, Apple, Facebook and Amazon to name a few. Khushita specialises in tech and patent policy coverage which featured in the Concurrences Antitrust Writing Awards. Previously as a financial journalist for The Wall Street Journal and Dow Jones Newswires, she wrote about monetary policy and the bond and currency markets. Khushita studied journalism at Mumbai University, and received an Erasmus Mundus scholarship for a masters from universities in Germany and Austria.